LONDON, March 18 (Reuters) - Oxford's vaccine trial chief on
Thursday welcomed statements by European and British medical
regulators that the COVID-19 shot the university developed with
AstraZeneca should continue to be rolled out after
reports of blood clots.
"I welcome the news that both the MHRA and EMA have
reiterated that the vaccine’s benefits continue to outweigh any
potential risks, and the vaccine should continue to be
administered," said Andrew Pollard, Chief Investigator on the
Oxford Vaccine Trial.
"It is important that public health bodies monitor the roll
out of the vaccine, and safety has to be paramount with any new
medicine."
(Reporting by Alistair Smout, editing by Estelle Shirbon)